|
Surgical group(n=35) (%) |
Medical group(n=35) (%) |
Male |
29(82.86%) |
27(77.14%) |
Female |
6(17.14%) |
8(22.86%) |
Diabetes |
35(100%) |
35(100%) |
Central SBO |
10(28.57%) |
9(25.71%) |
No growth in culture |
11(31.43%) |
9(25.71%) |
Pseudomonas |
10(28.57%) |
14(40%) |
Fungal |
10(28.57%) |
5(14.29%) |
Mixed flora |
2(5.71%) |
5(14.29%) |
Klebsiella |
1(2.86%) |
2(5.71%) |
Bacteroids |
1(2.86%) |
0(0%) |
Antimicrobials given |
Antimicrobials given |
Antimicrobials
given |
Voriconazole |
18(51.43%) |
16(45.71%) |
Piperacillin |
17(48.57%) |
19(54.29%) |
Ciprofloxacin |
12(34.29%) |
11(31.43%) |
Ceftazidime |
9(25.71%) |
7(20%) |
Cefaperazone |
8(22.86%) |
7(20%) |
Linezolid |
4(11.43%) |
1(2.86%) |
Meropenem |
4(11.43%) |
2(5.71%) |
Vancomycin |
3(8.57%) |
1(2.86%) |
Minocycline |
5(14.29%) |
2(5.71%) |
Fluconazole |
4(11.43%) |
0(0%) |
Levofloxacin |
2(5.71%) |
2(5.71%) |
Clindamycin |
1(2.86%) |
0(0%) |